Breast CancerAnatobreastNCT03214419
Study First Step to Virtual Breast Cancer Localization
An observational study of Breast Cancer, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Radioisotopic and wire localizations suffer from several limitations. These techniques add another procedure prior to surgery, can be uncomfortable and entail additional cost. The aim is to develop a novel technique of breast tumor localization using preoperative magnetic resonance imaging (MRI) and breast optical… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- How many people
- 10 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2017to 1 Sep 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have been diagnosed with breast cancer by core needle biopsy and underwent a breast conservation surgery between 2016 et 2017 in the gynaecology unit of the Montpellier University Hospital.
Who may be able to join
- diagnosis of breast cancer by core needle bipsy
- aged 18 years or more
- who had a preoperative magnetic resonance imaging
- who had a preoperative 3D optical scan
- who had two intraoperative optical scans (with and without pen marking for tumor localisation
- who had a preoperative radioguided occult lesion localization
- who had a breast conservation surgery
- not opposed to the use of their personal health data.
Who cannot join
- patients aged under 18
- requiring tutorship or guardianship
- who had neoadjuvant therapy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Anatobreast : First Step to Virtual Breast Cancer Localization
Radioisotopic and wire localizations suffer from several limitations. These techniques add another procedure prior to surgery, can be uncomfortable and entail additional cost.
The aim is to develop a novel technique of breast tumor localization using preoperative magnetic resonance imaging (MRI) and breast optical scanning.
Read more
Patients with diagnosis of breast cancer who have had a preoperative MRI and 3D optical scans are included.
Optical scanning is done preoperatively and intraoperatively after tumor localization was marked on the breast using radioisotopic technique.
The MRI is then adjusted with the intraoperative optical scan to match the breast position at the time of surgery.
The investigators evaluate the efficiency for localization of breast lesion of the novel technique by comparison with radiosiotopic technique.
Read the detailed description
Breast cancer is the most commonly cancer diagnosed among women, with approximately 42000 women diagnosed with breast cancer annually in France. Incidence rates of breast cancer rose steadily from 1980 to 2005 due to the increasing use of screening mammography and longer life expectancy.
With advances in breast cancer screening techniques, many women now have malignant tumors detected before they become clinically palpable. For these women, breast conserving surgery (BCS) has become the preferred treatment option, comprising more than 75 % of surgeries in most breast cancer centers. The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer while simultaneously preserving the overall shape and appearance of the breast. For non palpable lesions, localization of the tumor prior to surgery is needed. The standard technique for such patients is wire localization. Wire localization suffers from several limitations. It adds another procedure prior to surgery, complicating and lengthening the process. It can be uncomfortable for the patient and entails additional cost. This technique requires the surgeon to estimate the 3-dimensional (3D) position of the cancer from 2-dimensional mammography images. Wire localized excision results in positive margins approximately 30-50 % of the time. These cases require additional surgery to remove the remaining cancer, which is both costly and emotionally difficult for patients.
Alternatives to wire localization have been tested. Radioguided occult lesion localization (ROLL) has been shown to be superior to wire localization with shorter risk having positive resection margins and shorter duration of localization and surgical excision.
Magnetic resonance imaging of the breast has been shown to be more sensitive than ultrasound or mammography for the detection of cancer. Despite this evidence, the use of MRI has not been demonstrated to produce better short-term outcomes: the prospective randomized COMICE trial failed to demonstrate a decrease in the positive margin rate and need for re-excision with the use of preoperative prone MRI. The COMICE study authors recognized that the inability of prone MRI to result in decreased positive margin rates might be due to the way the imaging data is presented to the surgeon, stating that ''techniques to ensure surgical precision is at an optimum need further examination.'' The shape of the breast during prone MR imaging (with the breast pendant in a bilateral imaging coil) is radically different from the supine, arm-extended position in the operating room (OR). Supine MRI more accurately replicates the surgical position. Indeed, a study by Sakakibara et al. randomized patients with DCIS to undergo wire localized or supine MRI- guided BCS and found the positive margin rate and resected tissue volume were lower in patients undergoing supine MRI-guided excision.
The aim is to develop a novel technique of MRI- guided breast tumor localization that incorporates preoperative prone MRI and uses a preoperative and intraoperative 3D optical scans to adjust the MRI image to the exact position in the operating room. This novel technique will provide the surgeons with 3D views and measurements of tumor shape and position within the breast as it appears during surgery.
METHODS
- Data collection Data are obtained from the database of the gynecologic department of the Montpellier University Hospital, using the Medicalization Program of the Information Systems. The patient who have had a BCS for breast cancer between 2016 and 2017 are selected. The investigator then include consecutively 10 patients who have had a preoperative MRI and a preoperative and intraoperative 3D optical scan of the chest and who meet eligibility criteria. A subject identification code is assigned by the investigator to each subject to anonymized the data. A subject identification code list allows the investigator to keep a confidential list of names of all the patients included in the study on the protected central computer server of Montpellier University Hospital. 1.1.Clinical data The source of clinical medical data is the patient's electronic medical record. The data recorded by the investigator include name, surname and date of birth of the patient, cup size, date of MRI, breast cancer localization, date of preoperative 3D optical scan, date of date of surgical procedure. 1.2.Optical scans Since 2016, in the gynecology department of Montpellier University Hospital, photographs of the chest are taken for each patient who undergoes a BCS. Preoperative, intraoperative and postoperative 3D optical scans are also done. Optical scanning are obtained with the sensor structure 3D scanning. Acquisitions take few minutes. Preoperatively and postoperatively, patients are on standing position, arms abducted 45° with anatomical landmarks marked on the surface of the skin (manubrium of sternum, xiphoid process, top edge of the mammary gland, submammary fold). Intraoperatively, the tumor is localized by radioguided occult lesion localization and is marked on the surface of the breast. Two acquisitions are taken, before and after the tumor has been localized, with patients placed on the supine position, arms abducted 90°. 1.3.Preoperative breast MRI The standard breast MRI protocol includes T2 sequences (anatomy and signal analysis), T1 gradient-echo sequences and injected dynamic 3D sequences (gadolinium-containing contrast agent). Patients are placed on the prone position, arms above the head, with both breasts hanging in the coil loops. MRI data are collected from the computer server of radiology department, anonymized with the subject identification code and then burned to CD. Digital Imaging and Communication in Medicine (DICOM) data are converted into MHD format.
- different steps to create a 3D personalized breast model 2.1. 3D reconstruction of MRI data The 3D reconstruction requires the segmentation of the anatomical elements within the 2D images. Segmentation is done using a computer software called Medical Image Segmentation Tool (MIST) which allows semi-automatic and manual segmentation of the following elements: tumor, mammary gland, sternum, skin, pectoralis major and minor muscles. The 3D reconstruction is then performed by an indirect volume rendering method, the marching cubes. Instant Mesh software is then used for post-processing. 2.2.Registration of 3D reconstruction to optical scans Image registration is the process of transforming different sets of data into one coordinate system. The registration problem is to find the optimal spatial transformation that matches the images. The benefits of using multimodal data have created a need for the development of highly accurate and robust multimodal image registration. Anatoreg, a software designed by Anatoscope, allows registration of a reference model to a target. In our study, the reference model is the 3D reconstruction obtained from breast MRI. 3D reconstruction data are included in a Sofa Modelling Language (SML) file to be read by the registration software. The target is the optical scan, previously processed thanks to Blender (artefacts removal, axis correction, correction of unit of measurement). The first step of registration is the Interaction Closest Point algorithm (ICP). The ICP algorithm searches for the closest point in the reference surface for each point in the target surface without any restrictions. The second step is the use of landmarks to improve the registration.
- Evaluation of the 3D breast model Tumor localization by this 3D breast model is then compared to the localization by ROLL. The intraoperative 3D optical scan gives us the tumor localization obtained by radioguided occult lesion localization thanks to pen marking left by the surgeon. The novel technique gives us a 3D model and the localization of the tumor visible by transparency. Comparison is done by superimposing both acquisitions.
- Conditions
- Breast Cancer
- Keywords
- Breast cancer, 3D Optical scanning, Preoperative MRI, Tumor localization
- Medical subject headings
- Breast Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of breast tumor localization obtained with the novel technique with the localization obtained with radioguided occult lesion localization
The novel technique gives a 3D model and the localization of the tumor visible by transparency.
The intraoperative 3D optical scan gives the tumor localization obtained by radioguided occult lesion localization thanks to pen marking left by the surgeon. The comparison is done by superimposing both acquisitions.
Measured: The primary outcome measure will be done when the recruitment process will be completed, for an average of two months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2017
- Study start1 Feb 2017
- Primary completion1 Jun 2017
- Study completion1 Sep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Collaborators
- AnatoScope Montpellier
- Responsible party
- Sponsor
- Investigators
- GAUTHIER RATHAT, Study director, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03214419
- Sponsor's protocol ID
- RECHMPL17_0092
- Acronym
- Anatobreast
- Status last verified
- Jul 2017
- First submitted
- 5 Jul 2017
- Last updated
- 5 Dec 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: NC
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anatobreast : First Step to Virtual Breast Cancer Localization
- ClinicalTrials.gov ID
- NCT03214419
- Acronym / sponsor ID
- Anatobreast / RECHMPL17_0092
- Conditions
- Breast Cancer
- Keywords
- Breast cancer, 3D Optical scanning, Preoperative MRI, Tumor localization
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Collaborators
- AnatoScope Montpellier
- Study start
- 1 Feb 2017 (actual)
- Primary completion
- 1 Jun 2017 (actual)
- Study completion
- 1 Sep 2017 (actual)
- First posted
- 11 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Radioisotopic and wire localizations suffer from several limitations. These techniques add another procedure prior to surgery, can be uncomfortable and entail additional cost.
The aim is to develop a novel technique of breast tumor localization using preoperative magnetic resonance imaging (MRI) and breast optical scanning.
Patients with diagnosis of breast cancer who have had a preoperative MRI and 3D optical scans are included.
Optical scanning is done preoperatively and intraoperatively after tumor localization was marked on the breast using radioisotopic technique.
The MRI is then adjusted with the intraoperative optical scan to match the breast position at the time of surgery.
The investigators evaluate the efficiency for localization of breast lesion of the novel technique by comparison with radiosiotopic technique.
Detailed description
Breast cancer is the most commonly cancer diagnosed among women, with approximately 42000 women diagnosed with breast cancer annually in France. Incidence rates of breast cancer rose steadily from 1980 to 2005 due to the increasing use of screening mammography and longer life expectancy.
With advances in breast cancer screening techniques, many women now have malignant tumors detected before they become clinically palpable. For these women, breast conserving surgery (BCS) has become the preferred treatment option, comprising more than 75 % of surgeries in most breast cancer centers. The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer while simultaneously preserving the overall shape and appearance of the breast. For non palpable lesions, localization of the tumor prior to surgery is needed. The standard technique for such patients is wire localization. Wire localization suffers from several limitations. It adds another procedure prior to surgery, complicating and lengthening the process. It can be uncomfortable for the patient and entails additional cost. This technique requires the surgeon to estimate the 3-dimensional (3D) position of the cancer from 2-dimensional mammography images. Wire localized excision results in positive margins approximately 30-50 % of the time. These cases require additional surgery to remove the remaining cancer, which is both costly and emotionally difficult for patients.
Alternatives to wire localization have been tested. Radioguided occult lesion localization (ROLL) has been shown to be superior to wire localization with shorter risk having positive resection margins and shorter duration of localization and surgical excision.
Magnetic resonance imaging of the breast has been shown to be more sensitive than ultrasound or mammography for the detection of cancer. Despite this evidence, the use of MRI has not been demonstrated to produce better short-term outcomes: the prospective randomized COMICE trial failed to demonstrate a decrease in the positive margin rate and need for re-excision with the use of preoperative prone MRI. The COMICE study authors recognized that the inability of prone MRI to result in decreased positive margin rates might be due to the way the imaging data is presented to the surgeon, stating that ''techniques to ensure surgical precision is at an optimum need further examination.'' The shape of the breast during prone MR imaging (with the breast pendant in a bilateral imaging coil) is radically different from the supine, arm-extended position in the operating room (OR). Supine MRI more accurately replicates the surgical position. Indeed, a study by Sakakibara et al. randomized patients with DCIS to undergo wire localized or supine MRI- guided BCS and found the positive margin rate and resected tissue volume were lower in patients undergoing supine MRI-guided excision.
The aim is to develop a novel technique of MRI- guided breast tumor localization that incorporates preoperative prone MRI and uses a preoperative and intraoperative 3D optical scans to adjust the MRI image to the exact position in the operating room. This novel technique will provide the surgeons with 3D views and measurements of tumor shape and position within the breast as it appears during surgery.
METHODS
- Data collection Data are obtained from the database of the gynecologic department of the Montpellier University Hospital, using the Medicalization Program of the Information Systems. The patient who have had a BCS for breast cancer between 2016 and 2017 are selected. The investigator then include consecutively 10 patients who have had a preoperative MRI and a preoperative and intraoperative 3D optical scan of the chest and who meet eligibility criteria. A subject identification code is assigned by the investigator to each subject to anonymized the data. A subject identification code list allows the investigator to keep a confidential list of names of all the patients included in the study on the protected central computer server of Montpellier University Hospital. 1.1.Clinical data The source of clinical medical data is the patient's electronic medical record. The data recorded by the investigator include name, surname and date of birth of the patient, cup size, date of MRI, breast cancer localization, date of preoperative 3D optical scan, date of date of surgical procedure. 1.2.Optical scans Since 2016, in the gynecology department of Montpellier University Hospital, photographs of the chest are taken for each patient who undergoes a BCS. Preoperative, intraoperative and postoperative 3D optical scans are also done. Optical scanning are obtained with the sensor structure 3D scanning. Acquisitions take few minutes. Preoperatively and postoperatively, patients are on standing position, arms abducted 45° with anatomical landmarks marked on the surface of the skin (manubrium of sternum, xiphoid process, top edge of the mammary gland, submammary fold). Intraoperatively, the tumor is localized by radioguided occult lesion localization and is marked on the surface of the breast. Two acquisitions are taken, before and after the tumor has been localized, with patients placed on the supine position, arms abducted 90°. 1.3.Preoperative breast MRI The standard breast MRI protocol includes T2 sequences (anatomy and signal analysis), T1 gradient-echo sequences and injected dynamic 3D sequences (gadolinium-containing contrast agent). Patients are placed on the prone position, arms above the head, with both breasts hanging in the coil loops. MRI data are collected from the computer server of radiology department, anonymized with the subject identification code and then burned to CD. Digital Imaging and Communication in Medicine (DICOM) data are converted into MHD format.
- different steps to create a 3D personalized breast model 2.1. 3D reconstruction of MRI data The 3D reconstruction requires the segmentation of the anatomical elements within the 2D images. Segmentation is done using a computer software called Medical Image Segmentation Tool (MIST) which allows semi-automatic and manual segmentation of the following elements: tumor, mammary gland, sternum, skin, pectoralis major and minor muscles. The 3D reconstruction is then performed by an indirect volume rendering method, the marching cubes. Instant Mesh software is then used for post-processing. 2.2.Registration of 3D reconstruction to optical scans Image registration is the process of transforming different sets of data into one coordinate system. The registration problem is to find the optimal spatial transformation that matches the images. The benefits of using multimodal data have created a need for the development of highly accurate and robust multimodal image registration. Anatoreg, a software designed by Anatoscope, allows registration of a reference model to a target. In our study, the reference model is the 3D reconstruction obtained from breast MRI. 3D reconstruction data are included in a Sofa Modelling Language (SML) file to be read by the registration software. The target is the optical scan, previously processed thanks to Blender (artefacts removal, axis correction, correction of unit of measurement). The first step of registration is the Interaction Closest Point algorithm (ICP). The ICP algorithm searches for the closest point in the reference surface for each point in the target surface without any restrictions. The second step is the use of landmarks to improve the registration.
- Evaluation of the 3D breast model Tumor localization by this 3D breast model is then compared to the localization by ROLL. The intraoperative 3D optical scan gives us the tumor localization obtained by radioguided occult lesion localization thanks to pen marking left by the surgeon. The novel technique gives us a 3D model and the localization of the tumor visible by transparency. Comparison is done by superimposing both acquisitions.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have been diagnosed with breast cancer by core needle biopsy and underwent a breast conservation surgery between 2016 et 2017 in the gynaecology unit of the Montpellier University Hospital.
Key inclusion criteria (8 listed)
- diagnosis of breast cancer by core needle bipsy
- aged 18 years or more
- who had a preoperative magnetic resonance imaging
- who had a preoperative 3D optical scan
- who had two intraoperative optical scans (with and without pen marking for tumor localisation
Key exclusion criteria (3 listed)
- patients aged under 18
- requiring tutorship or guardianship
- who had neoadjuvant therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparison of breast tumor localization obtained with the novel technique with the localization obtained with radioguided occult lesion localization
Time frame: The primary outcome measure will be done when the recruitment process will be completed, for an average of two months
The novel technique gives a 3D model and the localization of the tumor visible by transparency. The intraoperative 3D optical scan gives the tumor localization obtained by radioguided occult lesion localization thanks to pen marking left by the surgeon. The comparison is done by superimposing both acquisitions.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2017.
- Individual participant dataSharing planned: Undecided. NC
Related trials for Breast Cancer
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GAUTHIER RATHAT study director
University Hospital, Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of breast tumor localization obtained with the novel technique with the localization obtained with radioguided occult lesion localization (time frame: The primary outcome measure will be done when the recruitment process will be completed, for an average of two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2017.